This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Gemini Science, Inc., Keygene N.v., La Jolla Institute for Allergy and Immunology. Active years: 2006-2009.
Company Filing History:
1 out of 3 
1 out of 118 
1 out of 62 
Years Active: 2006-2009
Title: Innovations of Stephen P. Schoenberger
Introduction
Stephen P. Schoenberger is a notable inventor based in Encinitas, California. He has made significant contributions to the field of immunology, particularly in the development of therapeutic methods for treating tumors and infectious diseases. With a total of two patents to his name, his work has the potential to impact cancer treatment and vaccine development.
Latest Patents
Schoenberger's latest patents include innovative compositions involving CD40 binding molecules and CTL peptides for treating tumors. The disclosed method and composition aim to enhance the anti-tumor effect of peptide tumor vaccines by utilizing CD40 binding molecules alongside CTL-activating peptides. This composition is designed to activate cytotoxic T lymphocytes (CTLs) to target tumorous or infected cells effectively. Additionally, he has developed human anti-CD40 antibodies that can modulate CD40 activities, which are crucial for regulating cell proliferation in vivo.
Career Highlights
Throughout his career, Schoenberger has worked with prominent organizations such as Gemini Science, Inc. and the La Jolla Institute for Allergy and Immunology. His experience in these institutions has allowed him to advance his research and contribute to the scientific community significantly.
Collaborations
Schoenberger has collaborated with esteemed colleagues, including Toshifumi Mikayama and Nobuaki Takahashi. These partnerships have likely enriched his research and expanded the scope of his innovations.
Conclusion
Stephen P. Schoenberger's contributions to immunology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in cancer treatment and immunotherapy.